Physician profile
Thomas S Ahern
NPI 1073599858
$30,041.02
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $4,748 · 2021: $871 · 2022: $506.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $25,382.04 | 2019-2020 | |
| Acutus Medical, INC. | $1,784.41 | 2019-2022 | |
| Boston Scientific Corporation | $1,351.58 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $456.53 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $321.83 | 2019 | |
| Amgen INC. | $199.63 | 2019-2020 | |
| Biotronik INC. | $127.29 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $116.76 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $72.39 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $54.41 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $50.39 | 2019 | |
| Pfizer INC. | $32.70 | 2019 | |
| Philips North America LLC | $30.78 | 2020 | |
| Cvrx, INC. | $25.49 | 2022 | |
| Medtronic Vascular, INC. | $21.63 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $13.16 | 2021 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Ahern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.